TCGA-XF-AAMY-01A-11R-A42T-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 98.91590013
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.320
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.320
- NOTCH_SIGNALING+0.300
- MYOGENESIS+0.230
- APICAL_SURFACE+0.210
- UV_RESPONSE_DN+0.210
- APICAL_JUNCTION+0.180
- TGF_BETA_SIGNALING+0.150
- SPERMATOGENESIS+0.090
- COAGULATION+0.040
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.580
- MYC_TARGETS_V1-0.450
- OXIDATIVE_PHOSPHORYLATION-0.450
- INTERFERON_GAMMA_RESPONSE-0.420
- E2F_TARGETS-0.370
- ALLOGRAFT_REJECTION-0.360
- MTORC1_SIGNALING-0.360
- MYC_TARGETS_V2-0.360
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.360
- DNA_REPAIR-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | X8de42096.ef3e.4864.8ee1.2ee7672c1c82 | — | cohortSQ1 | 0.870 |
| 2 | SRR1313111 | — | A | 0.868 |
| 3 | s0122297 | — | — | 0.865 |
| 4 | TCGA-CN-4737-01A-01R-1436-07 | — | — | 0.850 |
| 5 | TCGA-56-8626-01A-11R-2403-07 | — | cohortSQ1 | 0.849 |
| 6 | TCGA-ZF-A9RC-01A-11R-A38B-07 | — | — | 0.844 |
| 7 | SRR8518437 | — | D | 0.843 |
| 8 | TCGA-DK-A3IQ-01A-31R-A32Y-07 | — | — | 0.842 |
| 9 | TCGA-CQ-7072-01A-21R-A30B-07 | — | — | 0.838 |
| 10 | TCGA-AO-A12C-01A-11R-A10J-07 | — | A | 0.838 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.320 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.320 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MYOGENESIS | 0.230 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.210 | Temsirolimus | — uncovered |
| UV_RESPONSE_DN | 0.210 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.180 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.150 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.090 | Inavolisib | — uncovered |
| COAGULATION | 0.040 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.040 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.040 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.020 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.020 | Inavolisib | — uncovered |